Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update

Garry M. Walsh* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with monoclonal antibody–based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5 and IL-13 having considerable potential as effective treatments for severe asthma. For the most part, anti-cytokine-based biologic therapies are more likely to give significant clinical benefit in carefully selected patient populations that take asthma phenotypes and endotypes into account.
Original languageEnglish
Pages (from-to)1237-1244
Number of pages8
JournalExpert opinion on biological therapy
Issue number10
Early online date25 Jun 2020
Publication statusPublished - 2 Oct 2020

Bibliographical note

Funding: This paper is not funded.


  • il-5
  • eosinophils
  • biologics
  • mepolizumab
  • reslizumab
  • benralizumab


Dive into the research topics of 'Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update'. Together they form a unique fingerprint.

Cite this